VIR Stock Forecast: Vir Biotechnology, Inc. Price Predictions for 2026-2027
The 8 Wall Street analysts covering Vir Biotechnology, Inc. hold a median 12-month price target of $23 — +174.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 95 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Vir Biotechnology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Accruals (38): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
VIR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on VIR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +174.5% from it.
Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Nov 2026 | Evercore ISI Group | Maintains | Outperform | $22 → $25 |
| 10 Nov 2026 | Morgan Stanley | Maintains | Overweight | $25 → $28 |
| 9 Nov 2026 | HC Wainwright & Co. | Reiterates | Buy | $22 |
| 9 Nov 2026 | Needham | Maintains | Buy | $20 → $24 |
| 5 Nov 2026 | Needham | Maintains | Buy | $18 → $20 |
| 7 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $20 → $22 |
| 11 June 2026 | Morgan Stanley | Maintains | Overweight | $23 → $27 |
| 3 June 2026 | Leerink Partners | Maintains | Outperform | — |
| 4 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 25 Feb 2026 | Barclays | Maintains | Overweight | — |
| 24 Feb 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 24 Feb 2026 | Morgan Stanley | Maintains | Overweight | — |
| 24 Feb 2026 | Needham | Maintains | Buy | — |
| 9 Feb 2026 | Needham | Reiterates | Buy | — |
| 30 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Sept 2025 | Evercore ISI Group | Initiates | Outperform | — |
| 27 Aug 2025 | B of A Securities | Upgrade | Buy | — |
| 11 July 2025 | Raymond James | Initiates | Outperform | — |
| 22 May 2025 | Needham | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for VIR.
This page is one stock. Monday covers all of them.
VIR appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
VIR vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Vir Biotechnology, Inc. returned +50.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
VIR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 5.2×
- Price / book
- 1.6×
- EV / EBITDA
- —
Cheaper than 21% of US stocks
Cheaper than 52% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 100.0%
- Operating margin
- −70.2%
- Net margin
- —
Higher than 99% of US stocks
Higher than 16% of US stocks
- Return on equity
- −21.8%
- Return on assets
- −12.5%
- Dividend yield
- —
Higher than 31% of US stocks
Higher than 25% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Vir Biotechnology, Inc. has a market value of $1.6B and an enterprise value of $1.1B.
Revenue in the twelve months to 30 June 2026: $302.6M. The latest quarter grew 23075.1% year on year.
Net income over the same four quarters: −$251.7M, a −83.2% net margin.
Diluted earnings per share, trailing twelve months: −$1.86.
Free cash flow in the twelve months to 30 June 2026: −$203.6M.
Vir Biotechnology, Inc. employs 367 people — $824K of revenue per employee.
Data provided by Twelve Data
VIR and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at VIR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Vir Biotechnology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about VIR
What is the VIR stock price forecast for 2026-2027?
The 8 Wall Street analysts covering Vir Biotechnology, Inc. have a median 12-month price target of $23, with estimates ranging from $17 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is VIR stock a buy right now?
Of the 8 analysts covering Vir Biotechnology, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vir Biotechnology, Inc. 95 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank VIR?
As at 21 Nov 2026, Vir Biotechnology, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
Will VIR stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts implies +174.5% from the last close, and Ticker Nerd's factor model ranks Vir Biotechnology, Inc. 95 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the VIR stock forecast for 2030?
No analyst covering Vir Biotechnology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VIR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $30 over the next 12 months.
How has VIR stock performed over the past year?
Vir Biotechnology, Inc. returned +50.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Vir Biotechnology, Inc. do?
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer. The company centers its work on immune-based approaches, including antibody therapeutics and T cell-engaging technologies, to address conditions with significant unmet medical need.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer. The company centers its work on immune-based approaches, including antibody therapeutics and T cell-engaging technologies, to address conditions with significant unmet medical need. Its current portfolio includes programs for chronic hepatitis delta and chronic hepatitis B, alongside multiple solid-tumor candidates built on its PRO-XTEN masking platform. Vir Biotechnology also maintains preclinical research across infectious diseases and oncology, reflecting a pipeline that spans both treatment and prevention. Headquartered in San Francisco, California, Vir Biotechnology plays a role in the broader biotechnology market as a research-driven developer of advanced therapeutic candidates.
CEO Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. · 367 employees · United States · https://www.vir.bio